Glenmark Therapeutics launches generic Pataday Twice Daily Relief, targeting $26.4M market.

Glenmark Therapeutics Inc., a US subsidiary of Glenmark Pharmaceuticals, launched Olopatadine Hydrochloride Ophthalmic Solution 0.1% (OTC), a generic version of Pataday Twice Daily Relief, targeting a market with $26.4M annual sales. Fabio Moreno, Head of OTC Sales & Marketing, expressed excitement about the launch, emphasizing the company's commitment to meeting market needs and providing high-quality OTC solutions.

August 19, 2024
7 Articles